MedTrace Logo

Gender-sensitive Enhancement of Common Weight Loss Strategies for Overweight and Obesity

NCT04080193 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2022-05-09

No results posted yet for this study

Summary

The major aim of the proposed study is to develop a gender-sensitive individually tailored add-on intervention that focusses on improving individual gender-specific SIRs (subjective illness representations) in obese or overweight individuals. We will investigate whether this will improve compliance with and long-term success of common weight loss interventions. The effectiveness of this intervention in every-day-life with regard to weight-related behavioral changes and weight loss will be evaluated within a randomized controlled setting.To enhance the applicability of the intervention in every-day-life and its dissemination we plan to develop a smart-phone-based intervention.

Conditions

Interventions

BEHAVIORAL

Smartphone-based interventional trial

According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.

Sponsors & Collaborators

  • Department of Psychosomatic Medicine, LWL University Hospital Bochum

    collaborator UNKNOWN

  • Otto-Friedrich-University Bamberg

    lead OTHER

Principal Investigators

  • Sabine Steins-Löber, Prof. Dr. · Otto-Friedrich-University Bamberg

  • Stephan Herpertz, Prof. Dr. · Department of Psychosomatic Medicine, LWL University Hospital Bochum

  • Jörg Wolstein, Prof. Dr. · Otto-Friedrich-University Bamberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-07
Primary Completion
2021-12-22
Completion
2022-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080193 on ClinicalTrials.gov